Squarepoint Ops LLC reduced its stake in shares of Avadel Pharmaceuticals PLC. (NASDAQ: AVDL) by 49.6% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 134,221 shares of the company's stock after selling 131,864 shares during the period. Squarepoint Ops LLC owned approximately 0.14% of Avadel
- Data expected in Q2 2026 - DUBLIN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced the completion of patient enrollment in REVITALYZ, a Phase 3 trial evaluating LUMRYZTM (sodium oxybate) extended-release oral suspension as a potential treatment for idiopathic hypersomnia (IH). REVITALYZ is a double-blind, placebo-controlled, randomized withdrawal, multicenter Phase 3 trial designed to evaluate the efficacy and safety of LUMRYZ given as a once-at-bedtime dose in IH.
NEW YORK, Dec. 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Avadel Pharmaceuticals plc (NASDAQ: AVDL)'s sale to Alkermes plc.
AWM Investment Company Inc. raised its position in Avadel Pharmaceuticals PLC. (NASDAQ: AVDL) by 671.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 316,189 shares of the company's stock after purchasing an additional 275,189 shares during the quarter. AWM Investment Company
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Avadel Pharmaceuticals (NASDAQ: AVDL - Get Free Report) and Nuvilex (NASDAQ: PMCB - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation. Risk and Volatility Avadel Pharmaceuticals has a beta of
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 17(A) (AS AMENDED BY SECTION 3 OF APPENDIX 4) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) FOR IMMEDIATE RELEASE DUBLIN, Dec. 01, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors of Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporated in Ireland (the “Company” or “Avadel”) and the board of directors of Alkermes plc, a public limited company incorporated in Ireland (“Alkermes”), reached agreement on the terms of an offer for the Company by Alkermes, pursuant to which Alkermes will acquire the entire issued and to be issued ordinary share capital of the Company (the “Proposed Transaction”).
Handelsbanken Fonder AB purchased a new position in shares of Avadel Pharmaceuticals PLC. (NASDAQ: AVDL) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 34,100 shares of the company's stock, valued at approximately $302,000. Other hedge funds and other
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
